To the Editor:
In value. For the Roche and Abbott methods, the in-house results from the manufacturers were close to the target, but the peer group means of their customers were higher. For the Ortho VITROS method, the laboratories obtained lower values, and the manufacturer's in-house result was somewhere between the target value and the customers' values. We cannot exclude the possibility that some laboratories reported unconjugated bilirubin ("Bu") and the sum of bilirubin mono-and diglucuronide ("Bc"), although we explicitly asked VITROS users to report total bilirubin ("TBIL"). We were unable to clarify the method used upon retrospective inquiry of VITROS users.
From the external qualityassessment survey performed in 2009, it appears that recalibration of total bilirubin was "in progress" for the Roche and Abbott methods, which caused undesirably high interlaboratory variation. Results for the Beckman Coulter and Siemens/ Bayer methods were high, compared with the target value of the Doumas reference measurement procedure, suggesting that calibration traceability with the certified reference materials and/or value assignment by reference laboratories with listed reference measurement procedures (4 ), both available from the JCTLM, have not been achieved. From a clinical point of view, the effect of restandardization by Ϫ10% to Ϫ20% is not very dramatic at commonly observed "adult" bilirubin concentrations of 20 -80 mol/L; however, restandardization of total bilirubin will affect the clinical decision to start or stop treatment at concentrations usually seen in neonates (100 -600 mol/L), owing to the specific treatment thresholds or decision limits for phototherapy and blood-exchange transfusion (5 ) .
We conclude that notwithstanding the appearance of European In Vitro Diagnostic Directive 98/79/EC in 1998 and the foundation of the JCTLM in 2002, standardization has not been achieved. In addition, standardization of total bilirubin is complex, because the measurand is not unequivocally defined and the matrix may contain a mixture of bilirubin species (unconjugated, mono-and diconjugated, albumin-bound), which pose additional challenges.
Finally, because bilirubin restandardization has clinical consequences for the treatment of jaundiced neonates, the Chemistry Section of the SKML, in close collaboration with Dutch neonatologists, specifically aims to focus in 2010 on the analytical and clinical performance of commutable highconcentration neonatal bilirubin samples.
